Pediatric depression: is there evidence to improve evidence-based treatments?
Pediatric depression: is there evidence to improve evidence-based treatments?
复制标题
DOI：
10.1111/j.1469-7610.2008.02037.x
复制
发表时间：
2009-01-01
影响因子：
7.6
通讯作者：
Maalouf, Fadi T.
中科院分区：
文献类型：
--
作者：
Brent, David A.;Maalouf, Fadi T.
尽管我们治疗儿童和青少年抑郁症的能力已经取得了进步，但基于证据的治疗方法仍然会导致许多患者出现残留症状。我们对早发性抑郁症的认知、情感和生态方面的理解的进步，有可能导致抑郁症的评估和治疗的改进。寻找内部表型，即与抑郁症相关的特征，介导抑郁症的家族传播，并由基因决定，可能有助于了解病因和个性化治疗。然而，治疗的进步也可能来自于生物标志物的鉴定，即与治疗结果相关或介导治疗结果的可改变的神经认知、生理或生化指标。更有效的治疗方法可能来自于能够针对患者的认知、情感和发展概况进行个性化干预。
Although there have been advances in our ability to treat child and adolescent depression, use of evidence-based treatments still results in many patients with residual symptoms. Advances in our understanding of cognitive, emotional, and ecological aspects of early-onset depression have the potential to lead to improvements in the assessment and treatment of depression. A search for endophenotypes, i.e., traits that are related to depression, mediate the familial transmission of depression, and are genetically determined, may help in understanding etiology and in personalizing treatment. However, advances in treatment may also come from the identification of biomarkers, i.e., modifiable neurocognitive, physiological, or biochemical indices that are correlated with, or mediate, treatment outcome. More effective treatments may emerge from being able to personalize interventions to the patient's cognitive, emotional, and developmental profile.